Kiniksa Announces FDA Approval of Arcalyst (rilonacept) for Recurrent Pericarditis
HAMILTON, Bermuda, March 18, 2021 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio […]
TUESDAY, Sept. 22, 2020 — From 2008 to 2017, there were decreases in the rates of recurrent myocardial infarction (MI), […] (HealthDay)—Dabigatran is not superior to aspirin for preventing recurrent stroke in patients with recent history of embolic stroke of undetermined […] London UK – 19 March 2019 — TESARO, an oncology-focused business acquired by GlaxoSmithKline plc (LSE/NYSE: GSK), announced today the presentation […]Recurrent
Rates of Recurrent MI Declined Among U.S. Women and Men
Dabigatran doesn’t beat aspirin for preventing recurrent stroke
Data From GARNET Study Indicates Robust Activity of Dostarlimab in Patients with Advanced or Recurrent Endometrial Cancer